// App-Quantinova.ai

S146 : VENETOCLAX IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA WITH 17P DELETION: 6-YEAR FOLLOW-UP AND GENOMIC ANALYSES IN A PIVOTAL PHASE 2 TRIAL

Researchers

Presenter

  • Stephan Stilgenbauer

Principal Investigators

  • Eugen Tausch

  • Andrew W. Roberts

  • Matthew S. Davids

  • Barbara Eichhorst

  • Michael Hallek

  • Peter Hillmen

  • Christof Schneider

  • Sebastian Bttcher

  • Relja Popovic

  • Majd T. Ghanim

  • Michael Moran

  • Wendy J. Sinai

  • Xifeng Wang

  • Nabanita Mukherjee

  • Brenda Chyla

  • William G. Wierda

  • John F. Seymour

Medical Centers

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • AbbVie, Inc., North Chicago, IL

  • Division of Internal Medicine,Medical Clinic III-Hematology, Oncology and Palliative Medicine, Rostock University Medical Center,Rostock,Allemagne

  • Division of Internal Medicine,Medical Clinic III-Hematology, Oncology and Palliative Medicine, Rostock U

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Leeds Teaching Hospitals NHS Trust,Leeds,Verenigd Koninkrijk

  • Leeds Teaching Hospitals NHS Trust,Leeds,Verenigd Koninkrijk

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • AbbVie Inc ,North Chicago, IL,États-unis

  • AbbVie Inc ,North Chicago, IL,Estados Unidos

  • Peter MacCallum Cancer Centre, Royal Melbourne Hospital, and University of Melbourne

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • University of Texas MD Anderson Cancer Center, Houston, Texas, United States

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Division of CLL,Internal Medicine III, Ulm University,Ulm,Deutschland

  • Division of CLL,Internal Medicine III, Ulm University,Ulm,Deutschland

  • Division of CLL,Internal Medicine III, Ulm University,Ulm,Deutschland

  • Department 1 for Internal Medicine, Center for Integrated Oncology Koln-Bonn, University Hospital Cologne, Cologne, Germany

  • The University of Tokyo

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Leeds Teaching Hospitals, NHS Trust,Leeds,Reino Unido

  • Department of Medical Oncology, Dana Farber Cancer Institute, Boston, MA

  • Medical Oncology,Dana-Farber Cancer Institute,Boston,Vereinigte Staaten

  • AbbVie Inc., North Chicago, Illinois, United States

  • Division of CLL,Internal Medicine III, Ulm University,Ulm,Deutschland

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Leeds Teaching Hospitals, NHS Trust,Leeds,Reino Unido

  • Department of Internal Medicine III ,

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • AbbVie Inc ,North Chicago, IL,Vereinigte Staaten

  • The University of Texas, MD Anderson Cancer Center,Houston, TX,Verenigde Staten

  • Division of Internal Medicine,Medical Clinic III-Hematology, Oncology and Palliative Medicine, Rostock University Medical Center,Rostock,Allemagne

  • Department of Radiation Oncology, Dana-Farber Cancer Institute Boston MA United States

  • Division of CLL,Internal Medicine III, Ulm University,Ulm,Deutschland

  • Division of CLL,Internal Medicine III, Ulm University,Ulm,Deutschland

  • AbbVie Inc ,North Chicago, IL,Stati Uniti

Locations

  • Germany

  • United States

  • Australia

  • United Kingdom

  • Turkey

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic Lymphocytic Leukemia

Biomarkers

  • N/A

Drug/Treatment

  • Venetoclax

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • NCT01889186

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved